Company intelligence / Profile preview
HomeoTherapy
Incheon, South Korea
- Ownership
- Private
- Development stage
- Other
01
Overview
HomeoTherapy was a South Korea-based private biotech company focused on mesenchymal stem cell therapeutics and regenerative medicine. The company sponsored a Phase 1 clinical study of Homeo-GH, an allogeneic bone marrow-derived clonal mesenchymal stem cell therapy for acute and chronic graft-versus-host disease. Its technology centered on a subfractionation culturing method designed to derive single-cell clonal mesenchymal stem cell lines from bone marrow and support GMP manufacturing. Available evidence suggests the company is no longer active, with a Korean business registry indicating closure in 2014. Publicly visible pipeline information is limited and appears to center primarily on the Homeo-GH/cMSC program.
- Therapeutic areas
- Immunology
- Modalities
- Cell therapyStem cell therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on HomeoTherapy.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HomeoTherapy.